RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating

Core Insights - Viridian Therapeutics, Inc. (NASDAQ:VRDN) is recognized as one of the 10 Fastest Growing NASDAQ Stocks to Buy [1] - The company is preparing for a potential commercial launch of its treatment for thyroid eye disease in mid-2026, contingent on regulatory approval [2] - Recent earnings reports indicate a Q4 EPS of ($1.08), which was below the consensus estimate of ($1.00), and Q4 revenue of $132,000, significantly lower than the consensus of $15.75 million [4] Price Target Adjustments - RBC Capital has lowered its price target for Viridian Therapeutics to $42 from $45 while maintaining an Outperform rating, citing the company's positioning for a transition to commercial operations in 2026 [2] - Jefferies has raised its price target to $45 from $44, affirming a Buy rating, and noted that all key events are on track, with a focus on upcoming Phase 3 trial results [3] Company Developments - The company is advancing its pipeline with the BLA filing for veligrotug under Priority Review and a PDUFA target date set for June 30, 2026 [4] - The submission of the MAA to the EMA is aimed at expanding the global market opportunity for veligrotug [4] - Upcoming topline data for elegrobart from the REVEAL-1 trial is expected next month, which is crucial for establishing both veligrotug and elegrobart as foundational therapies for thyroid eye disease [4]